RhumbLine Advisers
CERE

RhumbLine Advisers’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

RhumbLine Advisers’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-87,810
Closed -$3.59M – 4392
2024
Q2 		$3.59M Sell
87,810
-15,380
-15% -$640K ﹤0.01% 1577
2024
Q1 		$4.36M Buy
103,190
+8,893
+9% +$374K ﹤0.01% 1484
2023
Q4 		$4M Buy
94,297
+6,626
+8% +$190K ﹤0.01% 1552
2023
Q3 		$1.91M Sell
87,671
-597
-0.7% -$14.9K ﹤0.01% 1882
2023
Q2 		$2.81M Buy
88,268
+4,546
+5% +$140K ﹤0.01% 1721
2023
Q1 		$2.04M Buy
83,722
+3,960
+5% +$116K ﹤0.01% 1797
2022
Q4 		$2.52M Buy
79,762
+10,118
+15% +$286K ﹤0.01% 1661
2022
Q3 		$1.97M Buy
69,644
+7,277
+12% +$217K ﹤0.01% 1770
2022
Q2 		$1.65M Buy
62,367
+21,322
+52% +$605K ﹤0.01% 1874
2022
Q1 		$1.44M Buy
41,045
+4,312
+12% +$126K ﹤0.01% 1972
2021
Q4 		$1.19M Sell
36,733
-51
-0.1% -$1.8K ﹤0.01% 2137
2021
Q3 		$1.08M Buy
36,784
+8,540
+30% +$240K ﹤0.01% 2196
2021
Q2 		$724K Buy
+28,244
New +$404K ﹤0.01% 2392

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

RhumbLine Advisers's CERE Position: Q3 2024 in Review

RhumbLine Advisers sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 87,810 shares — an estimated $3.59M sold.

RhumbLine Advisers first reported a position in CERE in Q2 2021 and held it in 13 quarters. The position peaked at $4.36M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • RhumbLine Advisers reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 87,810 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $3.59M.
  • RhumbLine Advisers first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 13 quarters.
  • RhumbLine Advisers's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $4.36M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.